Avacta Share Discussion Threads

[pwhite73] 17/10/2024 08:38

AVA6000 or AVA600000000000000000.

It makes no difference. The weak link is preCISION it does not work. So whether using Doxorubicin or Exatecan the result is the same. THERE IS NO WARHEAD.

[jacktrax] 17/10/2024 08:35

This board is the most utter drivel board out of the lot , I am a cancer sufferer this year , I have had some brutal therapy , to think , in years to come my treatment could have been so much more efficient thanks to avacta. The majority here are FUD , and dudishes as a fellow cancer sufferer you are just twisted my friend , laters

[fieldhouse] 17/10/2024 08:23

Each to his own .
Avacta,in the past,AS called all the shots without independent verification.
The culture has now completely changed with extremely well qualified advisors who have looked at the masses of data and have now redrawn the map going forward.
Ava6000 demonstrated that the precision worked.
A huge new pipeline is in the offing. This is just the start of the next generation of precision.

[fieldhouse] 17/10/2024 08:23

Each to his own .
Avacta,in the past,AS called all the shots without independent verification.
The culture has now completely changed with extremely well qualified advisors who have looked at the masses of data and have now redrawn the map going forward.
Ava6000 demonstrated that the precision worked.
A huge new pipeline is in the offing. This is just the start of the next generation of precision.

[rajraj b] 17/10/2024 08:21

Now they've shown the world what they can do with a strong warhead with AVA6000( i.e. demonstrated the pathfinder) they're now showing the world what they can do with a drug so powerful that it was never used in its pure state. AVA6103 is not messing about.

[pwhite73] 17/10/2024 08:17

1347 - "or are they now tacitly admitting that AVA6000 was such a failure"

AVA6000 was not the failure as it contained the most successful anti-cancer drug in the world Doxorubicin. The failure is preCISION. It cannot release anti-cancer drugs into the tumour to any effect. There is no magical warhead. Taking AVA6000 to Phase 1 was the error and this is why it has been stuck at Phase 1a for three years and cannot be subjected to academic peer review.

If they go back to the drawing board (pre-clinical stages) with their next generation of preCISION drugs they never have to prove efficacy. This allows them to pump out RNS after RNS detailing the pre-clinical progress of AVA6103 and AVA7100 without having to prove clinical efficacy.

[baldrick1] 17/10/2024 08:16

You'll lose this time ..go and close ;)))

[1347] 17/10/2024 07:52

So again what happened to AVA3996, or are they now tacitly admitting that AVA6000 was such a failure (as their Affimer based tests were) that they are not proceeding with the two candidates they got from Arisaph?

"18 January 2022

Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023."

What happened with their last pre-clinical pipeline candidates, AVA-021, AVA-028, AVA-032? Seems they were all quietly dropped, hoping no-one would notice? Well some of us have.

Looks to me as if they just want to find some new pre-clinical candidates so they can kick off another 3 year Phase trial, have more placings to ‘advance’; them and they can dine out on this forever and a day.

I notice the announcements come just before the next payday loan payment is due, which I doubt will be paid by cash this time. I reckon ‘investorsR17; are getting played here.

[pwhite73] 17/10/2024 06:56

From a share price point of view the company is back on the right path. If it keeps its activities to the pre-clinical stage the ineffectiveness of preCISION is not publicly exposed. Taking AVA6000 to the clinical stage was the mistake they made.

[amanitaangelicus] 17/10/2024 06:52

At least with blue chippers the reporting reqs are way higher than the Aim Circus. Provides some protection,security - they still move. Banks are worth a trade due to tight spreads. Good luck!

[amanitaangelicus] 17/10/2024 06:48

At least with blue chippers the reporting reqs are way higher than the Aim Circus. Provides some protection,security - they still move. Banks are worth a trade due to tight spreads. Good luck!

[robers98] 17/10/2024 06:11

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP). The peptide is designed to disable the warhead before the cleavage step releases it directly in the tumor microenvironment. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism. The tumor-specificity of the warhead release and bystander effect optimization of our medicines provide unique benefits over traditional antibody drug conjugates.
First Gen pre|CISION® doxorubicin

Potential indications
Breast cancer, head and neck cancers, dedifferentiated liposarcoma

Second Gen pre|CISION® exatecan

Potential indications
Gastric cancer, triple negative breast cancer, small cell lung cancer, pancreatic ductal adenocarcinoma

Third Gen pre|CISION® FAP Affimer® (AffDC). Warhead not disclosed

Potential indications
Head and neck squamous cell cancers, non-small cell lung cancer, colorectal cancer

[cheshire pete] 16/10/2024 21:12

Thank you ama for your concern for me as a LTH. No need to worry though as doing very nicely thank you. I know you have concerns relating to the way things have happened at Avacta but do try and put them in perspective.
BTW I do trade shares, mostly blue chips, sometimes in and out several times a week. Comfortable trading blue chips as I find it easy to make money, avoid the shark infested waters on AIM though. Fear and media frenzy over what Reeves might do in her budget is throwing up good opportunities.

[amanitaangelicus] 16/10/2024 12:20

Flying on not much volume ...gonna be some juicy late trades I guess! Keep watching. Expect the traders to come out of the woodwork again! Pleased for the LTHs here ie Cheshire and Fieldhouse.

[baldrick1] 16/10/2024 11:56

Profits banked.More to come ;)

[amanitaangelicus] 16/10/2024 06:36

£1.20 or 40p ...take your pick.

[nico115] 16/10/2024 01:04

What's your price target here ?

[amanitaangelicus] 15/10/2024 08:11

Chesh still desperate to keep all genuine concerns of this blog, no matter what. Big Red Flag for any sane person. Chesh is the only LTH here who doesn't trade! Funny as. Pull the other one -

[cheshire pete] 14/10/2024 20:14

Golden cross would be good news indeed. It'd put the FUDsters banging on about LFT, former CEO, CLN and death spiral back in their box for a while. In any case, surely the period of the CLN would have had some relation to the anticipated duration of the trials and the finance needed.

[amanitaangelicus] 14/10/2024 16:00

I mentioned that Surface Transforms was a binary play a while back ...it.s all but died today. Awaiting the 'rescue plan' ...or read ' shaft management plan'. Aim takes no prisoners.
Not over here yet - beast of a mkt cap, minute revenues, net profit invisible - compare to Surface Transforms ...mkt cap £4.5m mkt cap ...orders in excess of £200m ( yes you read that right) With Aim the truth ,reality is always hard to get at,AND, it s rarely, yes rarely as good as peeps think. Be careful at this truly bonkers level. Good luck though ! You have a dream. Ooph.